A federal appeals court last week rejected a request from marijuana opponents to temporarily block the Trump administration's efforts to move marijuana from Schedule I to Schedule III. This ruling, while not guaranteeing the ultimate rescheduling, keeps the process alive. Tilray Brands (NASDAQ: TLRY) could potentially benefit from such a change, which would ease cannabis research and expand medical marijuana opportunities in the U.S.